Executive Summary
In a procedural order concerning provisional measures, the UPC addressed a request for confidentiality protection. The Court granted access restrictions on specific technical and business information submitted by A. Menarini Diagnostics s.r.l., classifying it as confidential. While rejecting the defendant's motion that all highlighted portions were secret, the ruling established strict rules governing who could view this sensitive data. This decision reinforces the UPC's commitment to balancing urgent proceedings with robust protection of proprietary information.
What the Court Held — Ratio Decidendi
The UPC ruled that Article 58 UPCA must be interpreted broadly to protect not only trade secrets but also general confidential information. The Court granted a request for confidentiality protection over specific technical descriptions and business figures, subject to strict access limitations.
Practitioner Note
This decision partially_granted relief to the petitioner. If you are facing a similar patent dispute before Milan (IT) Local Division, this precedent supports interim or final relief where the facts are comparable. The ratio regarding the applied tests is particularly relevant for strategy.
Related Cases
Sibio Technology LimitedvsAbbott Diabetes Care Inc.
In this Central Division revocation action, Sibio Technology Limited challenged the validity of Abbott Diabetes Care Inc.'s patent EP 3 831 283 B1. The core dispute centered on whether the device's design constituted an inventive step over prior art documents. The Court ultimately dismissed the revocation claim, finding that the claimed invention demonstrated sufficient inventive merit and was not invalidated by the cited prior art. The decision also addressed procedural issues regarding late-filed arguments and the application of Rule 75(3) RoP in subsequent actions, reinforcing principles of flexibility and efficiency within the UPC framework. This ruling provides clarity on how courts assess non-obviousness when a dramatic design change is involved.
Simulity Labs LimitedvsARM Limited (and associated entities)
This UPC Court of Appeal decision addressed a procedural dispute concerning the confidentiality of evidence (Exhibit 4) in an ongoing infringement action involving ARM and ICPillar. The Court rejected ICPillar's request to keep the exhibit confidential, prioritizing transparency for the main proceedings. Crucially, the court balanced this by granting both parties opportunities to amend their respective statements based on the newly available information, thereby addressing concerns about equality of arms.
Network System Technologies LLCvsVolkswagen AG
In this preliminary ruling, the UPC Local Division in Munich addressed multiple objections raised by Volkswagen AG and its affiliates against Network System Technologies LLC regarding patent EP 1 552 669 B1. The Court partially dismissed these objections, allowing the infringement action to proceed despite initial challenges concerning jurisdiction and standing. This decision emphasizes the UPC's commitment to case management efficiency (Art. 41.3 UPCA), deferring complex issues like damages and UK scope until the main proceedings.
Roche Diabetes Care GmbHvsTandem Diabetes Care, Inc.
In a significant preliminary order, the UPC Local Division Hamburg rejected the request by Tandem Diabetes Care to stay an infringement action concerning its t:slim X2 insulin pump. The court emphasized the efficiency of the UPC system, stating that it is appropriate for the local division to hear both the infringement claim and the pending revocation actions simultaneously. This ruling reinforces the principle that procedural delays should not impede the pursuit of patent rights when a joint hearing can ensure a uniform legal outcome.
Meril Italy SrlvsEdwards Lifesciences Corporation
This procedural order from the UPC Court of Appeal addressed requests for expedition in multiple appeals concerning EP 3 646 825, a patent covering a prosthetic heart valve. The court ultimately rejected Meril's pleas to accelerate the proceedings, citing that existing legal mechanisms could manage the risks associated with pending validity challenges. This decision reinforces the standard procedural timetable of the UPC unless exceptional circumstances are met.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.